Routine Blood Parameters Predict Invasive Aspergillosis Prognosis
|
By LabMedica International staff writers Posted on 19 Nov 2019 |
|
Image: Photomicrograph of a hematoxylin-eosin-stained human lung tissue specimen, harvested from a pulmonary aspergillosis patient. The histopathologic changes indicate the presence of Aspergillus sp. fungal organisms. Note the branching hyphae amongst the lung tissue (Photo courtesy of the Armed Forces Institute of Pathology).
Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems, e.g. those undergoing bone marrow transplantation. Symptoms include fever, chills, shock, delirium, seizures, and blood clots.
Acute invasive aspergillosis occurs when the immune system fails to prevent Aspergillus spores from entering the bloodstream via the lungs. Without the body mounting an effective immune response, fungal cells are free to disseminate throughout the body and can infect major organs such as the heart and kidneys. The patient may develop kidney failure, liver failure (causing jaundice), and breathing difficulties and death can occur quickly.
A large team of scientists working with the National University of Singapore (Singapore) performed a post-hoc secondary analysis of two multicenter randomized trials. The Global Comparative Aspergillosis Study (GCA, N=123) and the Combination Antifungal Study (CAS, N=251) constituted the discovery and validation cohorts respectively. The outcome measures were response to treatment and survival to 12 weeks. Interval platelet, galactomannan index (GMI) and C-reactive protein (CRP) levels prior and during anti-fungal treatment were analyzed.
The investigators reported that the 12-week survival was 70.7% and 63.7% for the GCA and CAS cohorts respectively. In the GCA cohort, every 10×109/L platelet count increase at week 2 and 4 improved 12-week survival odds by 6-18% (Odds ratio [OR] 1.06-1.18). Survival odds also improved 13% with every 10 mg/dL CRP drop at week 1 and 2 (OR 0.87). In the CAS cohort, week 2 platelet count was also associated with 12-week survival with 10% improved odds for every 10×109/L platelet increase (OR, 1.10). A GMI drop of 0.1 units was additionally found to increase the odds of treatment response by 3% at the baseline of week 0 (OR 0.97). Week 2 platelet and CRP levels performed better than GMI on ROC analyses for survival (area under ROC curve 0.76, 0.87 and 0.67 respectively). A baseline platelet count higher than 30×109/L clearly identified patients with > 75% survival probability.
The authors concluded that higher serial platelets were associated with overall survival while GMI trends were linked to invasive aspergillosis treatment response. Routine and simple laboratory indices may aid follow-up of response in invasive aspergillosis patients. The study was published on October 24, 2019 in the journal Clinical Microbiology and Infection.
Related Links:
National University of Singapore
Acute invasive aspergillosis occurs when the immune system fails to prevent Aspergillus spores from entering the bloodstream via the lungs. Without the body mounting an effective immune response, fungal cells are free to disseminate throughout the body and can infect major organs such as the heart and kidneys. The patient may develop kidney failure, liver failure (causing jaundice), and breathing difficulties and death can occur quickly.
A large team of scientists working with the National University of Singapore (Singapore) performed a post-hoc secondary analysis of two multicenter randomized trials. The Global Comparative Aspergillosis Study (GCA, N=123) and the Combination Antifungal Study (CAS, N=251) constituted the discovery and validation cohorts respectively. The outcome measures were response to treatment and survival to 12 weeks. Interval platelet, galactomannan index (GMI) and C-reactive protein (CRP) levels prior and during anti-fungal treatment were analyzed.
The investigators reported that the 12-week survival was 70.7% and 63.7% for the GCA and CAS cohorts respectively. In the GCA cohort, every 10×109/L platelet count increase at week 2 and 4 improved 12-week survival odds by 6-18% (Odds ratio [OR] 1.06-1.18). Survival odds also improved 13% with every 10 mg/dL CRP drop at week 1 and 2 (OR 0.87). In the CAS cohort, week 2 platelet count was also associated with 12-week survival with 10% improved odds for every 10×109/L platelet increase (OR, 1.10). A GMI drop of 0.1 units was additionally found to increase the odds of treatment response by 3% at the baseline of week 0 (OR 0.97). Week 2 platelet and CRP levels performed better than GMI on ROC analyses for survival (area under ROC curve 0.76, 0.87 and 0.67 respectively). A baseline platelet count higher than 30×109/L clearly identified patients with > 75% survival probability.
The authors concluded that higher serial platelets were associated with overall survival while GMI trends were linked to invasive aspergillosis treatment response. Routine and simple laboratory indices may aid follow-up of response in invasive aspergillosis patients. The study was published on October 24, 2019 in the journal Clinical Microbiology and Infection.
Related Links:
National University of Singapore
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Latest Microbiology News
- Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
